Global Plasma Derived Therapy Market Report and Forecast 2025-2034

Global Plasma Derived Therapy Market Outlook

The global plasma derived therapy market size was valued at USD 24.00 billion in 2024, driven by the increasing access to medical care across the globe. The market size is anticipated to grow at a CAGR of 6.9% during the forecast period of 2025-2034 to achieve a value of USD 43.75 billion by 2034.

Plasma Derived Therapy: Introduction

Plasma-derived medicinal products are majorly used in immunology, haemostasis, and intensive care to treat rare, serious, genetic and – in many cases – life threatening diseases or conditions. These include over 80 recognized primary immunodeficiency diseases, bleeding disorders such as haemophilia and von Willebrand disease, and other genetic disorders relating to missing or non-functioning proteins typically found in blood plasma. Although they affect a relatively small percentage of the population, most are chronic conditions.

Patients generally require regular infusions or injections throughout their lives, ranging from twice a week to once a month for a primary immunodeficiency. These therapies are a lifeline, allowing patients to live a relatively normal life or significantly extending life expectancy. Plasma is a key component in the production of PDMPs. PDMPs are derived from human plasma, which is collected from donors and processed into various products. Plasma is a strategic resource to produce PDMPs, and its availability is crucial for the treatment of patients with rare diseases.

Global Plasma Derived Therapy Market Analysis

The rising investment and funding by the governments in advanced technology, along with the rising capacity expansion by the key players is primarily driving the plasma derived therapy market growth.

Plasma derived medicinal products (PDMPs) play a crucial role in prophylaxis and treatment of patients suffering from immune deficiencies, autoimmune and inflammatory diseases, bleeding disorders, and a variety of congenital deficiency disorders as well. They are used for treatment or prevention of rare clinical conditions that affects around 5 out of 10,000 people. PDMPs can be divided into four categories which are replacement or substitution therapies, immune-modulating therapies, anti-inflammatory therapies, and therapies directed to plasma protein antagonist functions. The increasing demand for PDMPs is growing gradually which is driven by increased access to medical care globally, new product launches and indications, introduction of more patient-friendly applications, and diagnostic advances that are further fuelling the global plasma derived therapy market expansion.

The development and availability of PDMPs is also expected to face some challenges due to the small size of the patient population as it would keep the costs high for the development of medicines for rare diseases.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Global Plasma Derived Therapy Market Segmentations

Market Breakup by Product

• Immunoglobulin 

• Coagulation Factors 

• Albumin 

• Others

Market Breakup by Applications

• Hemophilia 

• Primary immunodeficiency disease 

• Idiopathic thrombocytopenic purpura 

• Others

Market Breakup by Region

• North America 

• Europe 

• Asia Pacific 

• Latin America 

• Middle East and Africa

Global Plasma Derived Therapy Market Overview

The rising geriatric population is contributing to the growth of the market. Factors such as increasing prevalence of genetic disorders, escalating use of plasma proteins in pharmaceuticals, surging autoimmune disorders, government initiatives, rising demand for albumin are also directly driving the global plasma derived therapy market development.

Factors such as increased use of immunoglobulin is also fueling the market growth. With evident improvement in diagnoses of rare diseases and earlier treatment of complex chronic diseases, the demand for PDTs has increased significantly over the last two decades. The demand for plasma derived medicinal products and therapies is increasing with, new products and indications, increased access to medical care, more patient-friendly applications, and diagnostic advances has also been adding further value to the plasma derived therapy market share. According to several international data resources it is observed that a large number of patients around the globe are not yet diagnosed with diseases that require PDMP treatment.

There are chances of these therapies becoming expensive to access in future but with rise in development of new products and expanding markets it is expected to avoid the chances of that happening which will further contribute to the demand of the plasma derived therapies in the market. There has also been an evident increase in collaborations between key players two develop new products and therapies to serve more patients which is also responsible for driving the market growth.

Plasma Derived Therapy Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• CSL Behring 

• Takeda Pharmaceutical Company Limited 

• BPL 

• ADMA Biologics 

• Biotest AG 

• Octapharma 

• Grifols 

• Kamada Pharmaceuticals 

• SK Plasma 

• Kedrion

Key Highlights of the Report